Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

IntelGenx and Endo Ink Pact for New Oral Film Product in U.S.

By IntelGenx Technologies Corp. | December 28, 2016

IntelGenx announces development and commercialization agreement with Endo Ventures.

IntelGenx Corp. announced that it has entered into a co-development and commercialization agreement with Endo Ventures Ltd. for a new product utilizing IntelGenx’ proprietary VersaFilm™ for the U.S. market.

Under the agreement, Endo has obtained certain exclusive rights to market and sell IntelGenx’ product in the U.S. IntelGenx will receive an upfront payment and future milestone payments. Endo and IntelGenx will share the profits of commercialization.

“We are thrilled to further strengthen our partnership with such a significant global pharmaceutical organization as Endo,” said Dr. Horst Zerbe, president and CEO of IntelGenx. “We see the completion of this deal as further validation of our VersaFilm™ technology and our ability to enter into high quality partnerships. IntelGenx continues to make tremendous progress in executing our strategy of becoming a global leader in pharmaceutical oral films.”

IntelGenx is an oral drug delivery company primarily focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. The Montreal-based company was established in 2003.

IntelGenx provides services to pharmaceutical partners. Its offerings include R&D, analytical method development, clinical monitoring, IP and regulatory services. The IntelGenx manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities. www.intelgenx.com.

(Credit: Marketwired)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50